FDA Issues Rebuttal to AstraZeneca Exclusivity Suit

Drug Industry Daily
A A
AstraZeneca’s lawsuit against the FDA over the exclusivity of one of its drugs is a “transparent” effort to stifle generic competition for the blockbuster anti-cholesterol drug Crestor, the FDA said in its response to the suit.

To View This Article:

Login

Subscribe To Drug Industry Daily